MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

NCT00374296 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Stopped The Clinical Development Program for MGCD0103 is being re-evaluated

Conditions

Myelogenous Leukemia, Acute
Myelodysplastic Syndromes

Interventions

DRUG: MGCD0103

Sponsor

Mirati Therapeutics Inc.